Skip to main content

Webinar: Simple Your Process: Target Validation to Product Characterization

Webinar Summary

Drug product characterization and target validation are critical steps in biopharmaceutical development. Both involve understanding the role of a certain biomolecule, such as protein, in a disease process. Traditionally, Western blots have been the default technology for confirming the presence or absence of a protein during these steps in drug development, but it suffers from a tedious and manual process that does not offer throughput or reproducibility. The Simple Western™ platform is the modern evolution of traditional immunoassay technologies and is uniquely suited to handle the rigorous needs of product characterization and drug target validation. It is a highly sensitive and fully automated system that is easy to use and accelerates the process by handling up to 96 samples in a single run. Further, Simple Western systems reduce variability to provide reproducible and fully quantitative data making product characterization and target validation easier and more efficient.

In this webcast, Dr. Sosic will describe how purified Fc-fusion recombinant protein was analyzed using Sally, a Simple Western system during product characterization and identification process. A side-by-side comparison of results from Simple Western and legacy Western blots will be demonstrated. Further, Mr. Vivier will provide examples of how the Simple Western system, Peggy, has been used for the characterization of animal models of neurodegeneration and how it can assist in the pharmacological validation of drug targets of cognition.



Zoran Sosic, Ph.D., Sr. Scientist, Biogen Idec

Richard Vivier, Research Scientist, Eli Lilly and Company, UK